Skip to content
value.today

Transgenomic Inc.

Total raised
$3 M
1 round on record
Latest round
$3 M
Dec 2011
First round on record
Dec 2011
Today
Went public
See the company page

Transgenomic Inc. is listed today as Precipio, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 10 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Transgenomic Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2017$8 MPrivate placement after listing$2 to $10 million

Transgenomic Inc.: Private sale, Jun 2017

Investors in this round

3 investors had bought by the notice of Jul 17, 2017: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl Iberger · Executive Officer
  • Ilan Danieli · Executive Officer, Director
  • Mark D. Rimer · Director
  • Michael A. Luther · Director
  • Robert M. Patzig · Director
  • Samuel D. Riccitelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Shares of Common and Preferred Stock issued pursuant to conversion of outstanding debt.”

Signed by Ilan Danieli, Ceo. Source: SEC Form D, newest notice filed Jul 17, 2017. Read the notice at the SEC.

equitySEC
Apr 2017$1 MPrivate placement after listingUnder $2 million

Transgenomic Inc.: Private sale, Apr 2017

Investors in this round

5 investors had bought by the notice of Apr 26, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$84,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Paul Kinnon · Executive Officer, Director
  • Doit L Koppler · Director
  • Michael L Luther · Director
  • Mya L Thomae · Director
  • Robert M Patzig · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Aegis Capital Corp. (CRD 15007) · New York, New YorkSold in CA, CT, NY

Remarks in the notice

  • On fees: “Aegis Capital Corp. received warrants to acquire 168,000 shares of Transgenomic, Inc. common stock”

Signed by Paul Kinnon, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 26, 2017. Read the notice at the SEC.

debt, optionsSEC
Jan 2016$2 MPrivate placement after listing$2 to $10 million

Transgenomic Inc.: Private sale, Jan 2016

Investors in this round

5 investors had bought by the notice of Jan 20, 2016: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$140,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Leon F. Richards · Executive Officer · Chief Accounting Officer
  • Paul Kinnon · Executive Officer, Director · President, Chief Executive Officer, Interim Chief Financial Officer and Secretary, Director
  • Doit L. Koppler, II · Director
  • Michael L. Luther · Director
  • Mya L. Thomae · Director
  • Robert M. Patzig · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, MinnesotaSold in CA, VA

Remarks in the notice

  • On fees: “In addition to the above, for $50, the Company issued to Craig-Hallum Capital Group LLC a 5 year warrant to purchase up to 107,527 shares of common stock with an exercise price of $1.21 per share, which will be exercisable beginning on July 8, 2016.”

Signed by Leon Richards, Chief Accounting Officer. Source: SEC Form D, newest notice filed Jan 20, 2016. Read the notice at the SEC.

equity, optionsSEC
Jul 2015$3 MPrivate placement after listing$2 to $10 million

Transgenomic Inc.: Private sale, Jul 2015

Investors in this round

2 investors had bought by the notice of Jul 17, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$212,783
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Leon F. Richards · Executive Officer
  • Paul Kinnon · Executive Officer, Director · President, Chief Executive Officer, Interim Chief Financial Officer and Secretary, Director
  • Doit L. Koppler, II · Director
  • John D. Thompson · Director
  • Michael A. Luther · Director
  • Mya A. Thomae · Director
  • Robert M. Patzig · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, MinnesotaSold in CA, MN

Remarks in the notice

  • On fees: “In addition to the above, for $50, the Company issued to Craig-Hallum Capital Group LLC a 5 year warrant to purchase up to 107,033 shares of common stock with an exercise price of $1.66 per share, which will be exercisable beginning on January 7, 2016.”

Signed by Leon Richards, Chief Accounting Officer. Source: SEC Form D, newest notice filed Jul 17, 2015. Read the notice at the SEC.

equity, optionsSEC
Dec 2014$2 MPrivate placement after listingUnder $2 million

Transgenomic Inc.: Private sale, Dec 2014

Investors in this round

8 investors had bought by the notice of Jan 26, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$46,250
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Leon F. Richards · Executive Officer
  • Paul Kinnon · Executive Officer, Director · President, Chief Executive Officer, Interim Chief Financial Officer and Secretary, Director
  • Doit L. Koppler, II · Director
  • John D. Thompson · Director
  • Michael A. Luther · Director
  • Robert M. Patzig · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, MinnesotaSold in IL, MN, NJ, NY

Remarks in the notice

  • On fees: “Craig-Hallum Capital Group LLC was issued an unsecured convertible promissory note in an aggregate principal amount of $46,250, which is convertible into shares of the common stock of Transgenomic, Inc., for acting as placement agent for the offering.”

Signed by Paul Kinnon, President, CEO, Interim CFO & Secretary. Source: SEC Form D, newest notice filed Jan 26, 2015. Read the notice at the SEC.

debt, optionsSEC
Oct 2014$2 MPrivate placement after listing$2 to $10 million

Transgenomic Inc.: Private sale, Oct 2014

Investors in this round

9 investors had bought by the notice of Oct 27, 2014: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark P. Colonnese · Executive Officer
  • Paul Kinnon · Executive Officer, Director · President and Chief Executive Officer, Director
  • Doit L. Koppler, II · Director
  • John D. Thompson · Director
  • Michael A. Luther · Director
  • Robert M. Patzig · Director
  • Rodney S. Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark P. Colonnese, Executive Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 27, 2014. Read the notice at the SEC.

equity, optionsSEC
Mar 2014$7 MPrivate placement after listing$2 to $10 million

Transgenomic Inc.: Private sale, Mar 2014

Investors in this round

3 investors had bought by the notice of Mar 14, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark P. Colonnese · Executive Officer
  • Paul Kinnon · Executive Officer, Director
  • Antonius P. Schuh · Director
  • Doit L. Koppler II · Director
  • Robert M. Patzig · Director
  • Rodney S. Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark P. Colonnese, Executive Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 14, 2014. Read the notice at the SEC.

equitySEC
Jan 2013$8 MPrivate placement after listing$2 to $10 million

Transgenomic Inc.: Private sale, Jan 2013

Investors in this round

32 investors had bought by the notice of Feb 6, 2013: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$575,190
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chad M. Richards · Executive Officer
  • Craig J. Tuttle · Executive Officer, Director · Director, President and Chief Executive Officer
  • Mark P. Colonnese · Executive Officer
  • Antonius P. Schuh · Director
  • Doit L. Koppler Ii · Director
  • Robert M. Patzig · Director
  • Rodney S. Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • CRAIG-HALLUM CAPITAL GROUP LLC (CRD 121395) · Minneapolis, MinnesotaSold in CA, CT, IL, MA, MN, NJ, NY, PA, TX, VA, WA
  • LAZARD CAPITAL MARKETS LLC (CRD 134736) · New York, New YorkSold in CA, CT, IL, MA, MN, NJ, NY, PA, TX, VA, WA

Signed by Mark P. Colonnese, Executive Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 6, 2013. Read the notice at the SEC.

equity, optionsSEC
Feb 2012$22 MPrivate placement after listing$10 to $50 million

Transgenomic Inc.: Private sale, Feb 2012

Investors in this round

56 investors had bought by the notice of Feb 13, 2012: 56 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,330,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brett J Frevert · Executive Officer
  • Chad J Richards · Executive Officer
  • Craig J Tuttle · Executive Officer, Director · DIRECTOR, PRESIDENT AND CEO
  • Antonius J Schuh · Director
  • Doit J Koppler Ii · Director
  • Robert J Patzig · Director
  • Rodney J Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, MinnesotaSold in CA, CO, IL, MA, MN, NY, OH, VA, WA, WI, WV

Signed by Brett L. Frevert, Chief financial officer. Source: SEC Form D, newest notice filed Feb 13, 2012. Read the notice at the SEC.

equity, optionsSEC
Dec 2011$3 MNo. 1$2 to $10 million

Transgenomic Inc.: Raise no. 1, Dec 2011

Investors in this round

3 investors had bought by the notice of Jan 13, 2012: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brett L Frevert · Executive Officer · CFO
  • Chad M Richards · Executive Officer · CHIEF COMMERCIAL OFFICER
  • Craig J Tuttle · Executive Officer, Director · DIRECTOR, PRESIDENT AND CEO
  • Antonius P Schuh · Director
  • Doit L Koppler Ii · Director
  • Robert M Patzig · Director
  • Rodney S Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brett L. Frevert, Cfo. Source: SEC Form D, newest notice filed Jan 13, 2012. Read the notice at the SEC.

debt, optionsSEC
Dec 2010$6 MIssued in a merger or acquisition$2 to $10 million

Transgenomic Inc.: Private sale, Dec 2010

Investors in this round

3 investors had bought by the notice of Jan 10, 2011: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$100,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brett Frevert · Executive Officer
  • Chad Richards · Executive Officer
  • Craig Tuttle · Executive Officer, Director
  • Katrina Fahlin · Executive Officer
  • Antonius Schuh · Director
  • Doit Koppler · Director
  • Robert Patzig · Director
  • Rodney Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Griffin Securities, Inc. (CRD 43229) · New York, New YorkSold in VA

Remarks in the notice

  • On a merger: “Proceeds from the offering were used to finance Transgenomic, Inc.'s acquisition of certain assets of Clinical Data, Inc. and PGxHealth, LLC.”

Signed by Craig Tuttle, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 10, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Precipio, Inc., its revenue in fiscal 2025 came from these product and service lines: Service revenue, net $50.75 million (95%).

    Annual report (SEC XBRL) · Dec 2025

  • Transgenomic Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2017).

    SEC Form D · Jul 2017

  • Revenue range over time, as stated in its notices: revenue between $5 million and $25 million in 2011; revenue between $1 million and $5 million in 2017.

    SEC Form D (revenue range) · Apr 2017

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jul 2017

Products and services#

No products or services of Transgenomic Inc. are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Transgenomic Inc.
InvestorKindAmountRoundRoleSource
David Seth CohenPersonnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Third Security Incentive 2010 LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Third Security Senior Staff 2008 LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Third Security Staff 2010 LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2011)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 3 investors.

Largest shareholders today

Institutions holding Precipio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Transgenomic Inc.
NameRoleNamed in
Carl IbergerExecutive officerJul 2017
Ilan DanieliExecutive officerJul 2017
Paul KinnonExecutive officerApr 2017
Leon F. RichardsChief Accounting OfficerJan 2016
Mark P. ColonneseExecutive officerOct 2014
Chad M. RichardsExecutive officerFeb 2013
Craig J. TuttleDirector, President and Chief Executive OfficerFeb 2013
Brett J FrevertExecutive officerFeb 2012
Chad J RichardsExecutive officerFeb 2012
Craig J TuttleDIRECTOR, PRESIDENT AND CEOFeb 2012
Brett L FrevertCFOJan 2012
Chad M RichardsCHIEF COMMERCIAL OFFICERJan 2012
Brett FrevertExecutive officerJan 2011
Chad RichardsExecutive officerJan 2011
Craig TuttleExecutive officerJan 2011
Katrina FahlinExecutive officerJan 2011
Ilan DanieliDirectorJul 2017
Mark D. RimerDirectorJul 2017
Michael A. LutherDirectorJul 2017
Robert M. PatzigDirectorJul 2017
Samuel D. RiccitelliDirectorJul 2017
Doit L KopplerDirectorApr 2017
Michael L LutherDirectorApr 2017
Mya L ThomaeDirectorApr 2017
Paul KinnonDirectorApr 2017
Robert M PatzigDirectorApr 2017
Doit L. Koppler, IIDirectorJan 2016
Michael L. LutherDirectorJan 2016
Mya L. ThomaeDirectorJan 2016
John D. ThompsonDirectorJul 2015
Mya A. ThomaeDirectorJul 2015
Rodney S. MarkinDirectorOct 2014
Antonius P. SchuhDirectorMar 2014
Doit L. Koppler IIDirectorMar 2014
Craig J. TuttleDirector, President and Chief Executive OfficerFeb 2013
Doit L. Koppler IiDirectorFeb 2013
Antonius J SchuhDirectorFeb 2012
Craig J TuttleDIRECTOR, PRESIDENT AND CEOFeb 2012
Doit J Koppler IiDirectorFeb 2012
Robert J PatzigDirectorFeb 2012

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.